Celldex to Present Dat at SITC, SNO Annual Meetings
October 21, 2013 at 12:31 PM EDT
Celldex Therapeutics, Inc. (Nasdaq: CLDX ) announced today that data from two of its clinical programs, the Phase 1 dose-escalation CDX-1127 study and the Phase 2 recurrent rindopepimut study, will be presented at two upcoming medical meetings, the Society for Immunotherapy of Cancer (SITC) and the Society of Neuro-Oncology (SNO), respectively. The Company also
